Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 157 entries
Sorted by: Best Match Show Resources per page
Engaged IT Experience Course to Enable the Future Workforce

Stem workforce diversity

Albina A.
GSID: iBeLg_jPo38J
R Prasad, C Traynor, A Albina - … of the 18th Annual Conference on …, 2017 - dl.acm.org

ABSTRACT Computer Science (CS) and Information Technology (IT) education needs to find new ways to boost students' interest in selecting and completing undergraduate degrees in these disciplines. In addition to retaining them in the major, we need to equip...

Cite
Prasad, R., Traynor, C., & Albina, A. (2017, September). Engaged IT Experience Course to Enable the Future Workforce. In Proceedings of the 18th Annual Conference on Information Technology Education (pp. 7-12).
Prasad, Rajesh, Carol Traynor, and Adam Albina. "Engaged IT Experience Course to Enable the Future Workforce." Proceedings of the 18th Annual Conference on Information Technology Education. 2017.
Copy Download .nbib Format: MLA
Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study.

Frontiers in pharmacology

Georgiopoulos G, Katsi V, Oikonomou D, Vamvakou G, Koutli E, Laina A, Tsioufis C, Nihoyannopoulos P, Tousoulis D.
PMID: 27536242
Front Pharmacol. 2016 Aug 03;7:235. doi: 10.3389/fphar.2016.00235. eCollection 2016.

BACKGROUND: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of...

Cite
Georgiopoulos G, Katsi V, Oikonomou D, et al. Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study. Front Pharmacol. 2016;7:235doi: 10.3389/fphar.2016.00235.
Georgiopoulos, G., Katsi, V., Oikonomou, D., Vamvakou, G., Koutli, E., Laina, A., Tsioufis, C., Nihoyannopoulos, P., & Tousoulis, D. (2016). Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study. Frontiers in pharmacology, 7235. https://doi.org/10.3389/fphar.2016.00235
Georgiopoulos, Georgios, et al. "Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study." Frontiers in pharmacology vol. 7 (2016): 235. doi: https://doi.org/10.3389/fphar.2016.00235
Georgiopoulos G, Katsi V, Oikonomou D, Vamvakou G, Koutli E, Laina A, Tsioufis C, Nihoyannopoulos P, Tousoulis D. Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study. Front Pharmacol. 2016 Aug 03;7:235. doi: 10.3389/fphar.2016.00235. eCollection 2016. PMID: 27536242; PMCID: PMC4971108.
Copy Download .nbib Format: NLM
Variation in patient-provider communication by patient's race and ethnicity, provider type, and continuity in and site of care: An analysis of data from the Connecticut Health Care Survey.

SAGE open medicine

Aseltine RH, Sabina A, Barclay G, Graham G.
PMID: 26835017
SAGE Open Med. 2016 Jan 13;4:2050312115625162. doi: 10.1177/2050312115625162. eCollection 2016.

OBJECTIVES: The purpose of this study is to examine the quality of patient-reported communication with their health care providers using data from a large, statewide survey of patients. We examine the relationship between patient's race and ethnicity, type of...

Cite
Aseltine RH, Sabina A, Barclay G, et al. Variation in patient-provider communication by patient's race and ethnicity, provider type, and continuity in and site of care: An analysis of data from the Connecticut Health Care Survey. SAGE Open Med. 2016;4:2050312115625162doi: 10.1177/2050312115625162.
Aseltine, R. H., Sabina, A., Barclay, G., & Graham, G. (2016). Variation in patient-provider communication by patient's race and ethnicity, provider type, and continuity in and site of care: An analysis of data from the Connecticut Health Care Survey. SAGE open medicine, 42050312115625162. https://doi.org/10.1177/2050312115625162
Aseltine, Robert H, et al. "Variation in patient-provider communication by patient's race and ethnicity, provider type, and continuity in and site of care: An analysis of data from the Connecticut Health Care Survey." SAGE open medicine vol. 4 (2016): 2050312115625162. doi: https://doi.org/10.1177/2050312115625162
Aseltine RH, Sabina A, Barclay G, Graham G. Variation in patient-provider communication by patient's race and ethnicity, provider type, and continuity in and site of care: An analysis of data from the Connecticut Health Care Survey. SAGE Open Med. 2016 Jan 13;4:2050312115625162. doi: 10.1177/2050312115625162. eCollection 2016. PMID: 26835017; PMCID: PMC4724761.
Copy Download .nbib Format: NLM
Golimumab for severe asthma.

Expert opinion on investigational drugs

Antoniu SA.
PMID: 19678804
Expert Opin Investig Drugs. 2009 Sep;18(9):1421-3. doi: 10.1517/13543780903136716.

BACKGROUND: In severe asthma anti-TNF-alpha therapies might be effective in improving disease control based on preclinical results and on clinical short-term data. However, the long-term efficacy and safety is not known.OBJECTIVE: To discuss the data on golimumab, an anti-TNF-alpha...

Cite
Antoniu SA. Golimumab for severe asthma. Expert Opin Investig Drugs. 2009;18(9):1421-3doi: 10.1517/13543780903136716.
Antoniu, S. A. (2009). Golimumab for severe asthma. Expert opinion on investigational drugs, 18(9), 1421-3. https://doi.org/10.1517/13543780903136716
Antoniu, Sabina A. "Golimumab for severe asthma." Expert opinion on investigational drugs vol. 18,9 (2009): 1421-3. doi: https://doi.org/10.1517/13543780903136716
Antoniu SA. Golimumab for severe asthma. Expert Opin Investig Drugs. 2009 Sep;18(9):1421-3. doi: 10.1517/13543780903136716. PMID: 19678804.
Copy Download .nbib Format: NLM
Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy.

Critical pathways in cardiology

Lakkis N, Tsyboulev V, Gibson CM, Murphy SA, Weintraub WS, DiBattiste PM, Cannon CP.
PMID: 18340309
Crit Pathw Cardiol. 2002 Dec;1(4):232-7. doi: 10.1097/00132577-200212000-00005.

In the TACTICS-TIMI-18 trial, patients with acute coronary syndrome were treated with aspirin, heparin, and tirofiban and were randomized to an invasive strategy with routine catheterization or to a conservative strategy with catheterization (only if the patient had objective...

Cite
Lakkis N, Tsyboulev V, Gibson CM, et al. Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy. Crit Pathw Cardiol. 2002;1(4):232-7doi: 10.1097/00132577-200212000-00005.
Lakkis, N., Tsyboulev, V., Gibson, C. M., Murphy, S. A., Weintraub, W. S., DiBattiste, P. M., Cannon, C. P. (2002). Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy. Critical pathways in cardiology, 1(4), 232-7. https://doi.org/10.1097/00132577-200212000-00005
Lakkis, Nasser, et al. "Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy." Critical pathways in cardiology vol. 1,4 (2002): 232-7. doi: https://doi.org/10.1097/00132577-200212000-00005
Lakkis N, Tsyboulev V, Gibson CM, Murphy SA, Weintraub WS, DiBattiste PM, Cannon CP. Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy. Crit Pathw Cardiol. 2002 Dec;1(4):232-7. doi: 10.1097/00132577-200212000-00005. PMID: 18340309.
Copy Download .nbib Format: NLM
Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666.

Expert opinion on investigational drugs

Antoniu SA.
PMID: 17302533
Expert Opin Investig Drugs. 2007 Mar;16(3):393-5. doi: 10.1517/13543784.16.3.393.

Systemic sclerosis (scleroderma) is a chronic debilitating disease that is caused by the occurrence of fibrotic changes and vascular abnormalities at various levels such as: skin, lungs, kidneys or heart. Lung involvement in scleroderma is represented by scleroderma interstitial...

Cite
Antoniu SA. Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666. Expert Opin Investig Drugs. 2007;16(3):393-5doi: 10.1517/13543784.16.3.393.
Antoniu, S. A. (2007). Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666. Expert opinion on investigational drugs, 16(3), 393-5. https://doi.org/10.1517/13543784.16.3.393
Antoniu, Sabina A. "Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666." Expert opinion on investigational drugs vol. 16,3 (2007): 393-5. doi: https://doi.org/10.1517/13543784.16.3.393
Antoniu SA. Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666. Expert Opin Investig Drugs. 2007 Mar;16(3):393-5. doi: 10.1517/13543784.16.3.393. PMID: 17302533.
Copy Download .nbib Format: NLM
Bosentan for the treatment of idiopathic pulmonary fibrosis.

Expert opinion on investigational drugs

Antoniu SA.
PMID: 18363525
Expert Opin Investig Drugs. 2008 Apr;17(4):611-4. doi: 10.1517/13543784.17.4.611.

No abstract available.

Cite
Antoniu SA. Bosentan for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2008;17(4):611-4doi: 10.1517/13543784.17.4.611.
Antoniu, S. A. (2008). Bosentan for the treatment of idiopathic pulmonary fibrosis. Expert opinion on investigational drugs, 17(4), 611-4. https://doi.org/10.1517/13543784.17.4.611
Antoniu, Sabina A. "Bosentan for the treatment of idiopathic pulmonary fibrosis." Expert opinion on investigational drugs vol. 17,4 (2008): 611-4. doi: https://doi.org/10.1517/13543784.17.4.611
Antoniu SA. Bosentan for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2008 Apr;17(4):611-4. doi: 10.1517/13543784.17.4.611. PMID: 18363525.
Copy Download .nbib Format: NLM
Fluticasone propionate in COPD airway inflammation: there is a partial effect.

Expert review of pharmacoeconomics & outcomes research

Antoniu SA, Donner CF.
PMID: 19807464
Expert Rev Pharmacoecon Outcomes Res. 2002 Oct;2(5):415-7. doi: 10.1586/14737167.2.5.415.

Chronic obstructive pulmonary disease is a mainly tobacco-related disease currently representing the fourth highest cause of mortality worldwide. It is characterized by progressive chronic airway obstruction, the underlying pathogenic mechanism being inflammatory. Currently, apart from neutrophils and macrophages, there...

Cite
Antoniu SA, Donner CF. Fluticasone propionate in COPD airway inflammation: there is a partial effect. Expert Rev Pharmacoecon Outcomes Res. 2002;2(5):415-7doi: 10.1586/14737167.2.5.415.
Antoniu, S. A., & Donner, C. F. (2002). Fluticasone propionate in COPD airway inflammation: there is a partial effect. Expert review of pharmacoeconomics & outcomes research, 2(5), 415-7. https://doi.org/10.1586/14737167.2.5.415
Antoniu, Sabina A, and Donner, Claudio F. "Fluticasone propionate in COPD airway inflammation: there is a partial effect." Expert review of pharmacoeconomics & outcomes research vol. 2,5 (2002): 415-7. doi: https://doi.org/10.1586/14737167.2.5.415
Antoniu SA, Donner CF. Fluticasone propionate in COPD airway inflammation: there is a partial effect. Expert Rev Pharmacoecon Outcomes Res. 2002 Oct;2(5):415-7. doi: 10.1586/14737167.2.5.415. PMID: 19807464.
Copy Download .nbib Format: NLM
Health status in COPD: current data and future trends.

Expert review of pharmacoeconomics & outcomes research

Antoniu SA, Mihaescu T, Carone M, Donner CF.
PMID: 19807496
Expert Rev Pharmacoecon Outcomes Res. 2003 Feb;3(1):57-65. doi: 10.1586/14737167.3.1.57.

In chronic obstructive pulmonary disease, health status is an important outcome for clinicians, the pharmaceutical industry and policy-makers. It has been assessed using both generic and disease-specific questionnaires. The generic questionnaire most frequently used in the context of chronic...

Cite
Antoniu SA, Mihaescu T, Carone M, et al. Health status in COPD: current data and future trends. Expert Rev Pharmacoecon Outcomes Res. 2003;3(1):57-65doi: 10.1586/14737167.3.1.57.
Antoniu, S. A., Mihaescu, T., Carone, M., & Donner, C. F. (2003). Health status in COPD: current data and future trends. Expert review of pharmacoeconomics & outcomes research, 3(1), 57-65. https://doi.org/10.1586/14737167.3.1.57
Antoniu, Sabina A, et al. "Health status in COPD: current data and future trends." Expert review of pharmacoeconomics & outcomes research vol. 3,1 (2003): 57-65. doi: https://doi.org/10.1586/14737167.3.1.57
Antoniu SA, Mihaescu T, Carone M, Donner CF. Health status in COPD: current data and future trends. Expert Rev Pharmacoecon Outcomes Res. 2003 Feb;3(1):57-65. doi: 10.1586/14737167.3.1.57. PMID: 19807496.
Copy Download .nbib Format: NLM
Adherence to inhaled therapy in COPD: effects on survival and exacerbations.

Expert review of pharmacoeconomics & outcomes research

Antoniu SA.
PMID: 20384558
Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):115-7. doi: 10.1586/erp.10.10.

Evaluation of: Vestbo J, Anderson JA, Calverley PMA et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 64, 939-943 (2009). In chronic diseases, adherence to inhaled therapy can impact treatment effectiveness and can influence disease...

Cite
Antoniu SA. Adherence to inhaled therapy in COPD: effects on survival and exacerbations. Expert Rev Pharmacoecon Outcomes Res. 2010;10(2):115-7doi: 10.1586/erp.10.10.
Antoniu, S. A. (2010). Adherence to inhaled therapy in COPD: effects on survival and exacerbations. Expert review of pharmacoeconomics & outcomes research, 10(2), 115-7. https://doi.org/10.1586/erp.10.10
Antoniu, Sabina A. "Adherence to inhaled therapy in COPD: effects on survival and exacerbations." Expert review of pharmacoeconomics & outcomes research vol. 10,2 (2010): 115-7. doi: https://doi.org/10.1586/erp.10.10
Antoniu SA. Adherence to inhaled therapy in COPD: effects on survival and exacerbations. Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):115-7. doi: 10.1586/erp.10.10. PMID: 20384558.
Copy Download .nbib Format: NLM
Self-management programs in chronic obstructive pulmonary disease: are they worthy?.

Expert review of pharmacoeconomics & outcomes research

Antoniu SA.
PMID: 19807345
Expert Rev Pharmacoecon Outcomes Res. 2003 Dec;3(6):681-3. doi: 10.1586/14737167.3.6.681.

Chronic obstructive pulmonary disease is a smoking-related progressive disease with an increasing prevalence and socioeconomic burden worldwide. Educational programs are usually components of rehabilitative strategies. Current intervention is through educational programs designed for chronic obstructive pulmonary disease patients. Among...

Cite
Antoniu SA. Self-management programs in chronic obstructive pulmonary disease: are they worthy?. Expert Rev Pharmacoecon Outcomes Res. 2003;3(6):681-3doi: 10.1586/14737167.3.6.681.
Antoniu, S. A. (2003). Self-management programs in chronic obstructive pulmonary disease: are they worthy?. Expert review of pharmacoeconomics & outcomes research, 3(6), 681-3. https://doi.org/10.1586/14737167.3.6.681
Antoniu, Sabina A. "Self-management programs in chronic obstructive pulmonary disease: are they worthy?." Expert review of pharmacoeconomics & outcomes research vol. 3,6 (2003): 681-3. doi: https://doi.org/10.1586/14737167.3.6.681
Antoniu SA. Self-management programs in chronic obstructive pulmonary disease: are they worthy?. Expert Rev Pharmacoecon Outcomes Res. 2003 Dec;3(6):681-3. doi: 10.1586/14737167.3.6.681. PMID: 19807345.
Copy Download .nbib Format: NLM
Salmeterol/fluticasone combination in COPD: is together better?.

Expert review of pharmacoeconomics & outcomes research

Antoniu SA, Mititiuc I.
PMID: 19807359
Expert Rev Pharmacoecon Outcomes Res. 2003 Apr;3(2):121-4. doi: 10.1586/14737167.3.2.121.

Chronic obstructive pulmonary disease represents one of the chronic conditions for which many therapies have become available during the last few decades. They are aimed at reducing symptoms such as dyspnea, cough and sputum and many of them are...

Cite
Antoniu SA, Mititiuc I. Salmeterol/fluticasone combination in COPD: is together better?. Expert Rev Pharmacoecon Outcomes Res. 2003;3(2):121-4doi: 10.1586/14737167.3.2.121.
Antoniu, S. A., & Mititiuc, I. (2003). Salmeterol/fluticasone combination in COPD: is together better?. Expert review of pharmacoeconomics & outcomes research, 3(2), 121-4. https://doi.org/10.1586/14737167.3.2.121
Antoniu, Sabina A, and Mititiuc, Irina. "Salmeterol/fluticasone combination in COPD: is together better?." Expert review of pharmacoeconomics & outcomes research vol. 3,2 (2003): 121-4. doi: https://doi.org/10.1586/14737167.3.2.121
Antoniu SA, Mititiuc I. Salmeterol/fluticasone combination in COPD: is together better?. Expert Rev Pharmacoecon Outcomes Res. 2003 Apr;3(2):121-4. doi: 10.1586/14737167.3.2.121. PMID: 19807359.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 157 entries